Proteom analysis in Serum of pediatric hemato-oncological patients with invasive aspergillosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031416

Enrollment

Registered

2023-03-03

Start date

2023-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B44.7

Interventions

Group 1: 20 pediatric hemato-oncological patients with presence of galactomannan in serum and clinical signs of invasive aspergillosis Group 2: 20 pediatric hemato-oncological patients without detect

Eligibility

Sex/Gender

All

Age

6 Months to No maximum

Inclusion criteria

Inclusion criteria: hematooncologic primary disease retained serumsamples with detection of galactomannan informed consent given

Exclusion criteria

Exclusion criteria: other kind of immunosuppression therapy with PLASMA-LYTE™ in a timeframe of four weeks to when the serumsample was taken no retained serum samples available no informed consent given

Design outcomes

Primary

Measure	Time frame
Proteomanalysis of retained serum-samples of the patient collctive at timepoints before and at the time of galactomannan-detection as well as serum-samples of the controll-collektives by mass-spectrometry.	—

Secondary

Measure	Time frame
Analysis of serumprotein-expressionlevels and clinical data for identification of potential biomarkers of invasive aspergillosis.	—

Countries

Germany

Contacts

Public ContactHanna Gölz

Institut für medizinische Mikrobiologie und Hygiene, Universitätsklinikum Freiburg

hanna.goelz@uniklinik-freiburg.de+497612036510

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026